Capromorelin
A Phase II clinical trial investigated the effects of capromorelin on
body composition and functional performance in healthy elderly people.
At 12 months, capromorelin significantly increased lean body mass and
the ability to climb stairs compared to placebo. However, this study was
terminated early because results at 12 months were not considered a
continuation of this study [43]. As the aging process is not
considered a pathological condition by the FDA, capromorelin must offer
excellent results, as a survival benefit in this case. population or be
applied to other clinical indications. Capromorelin has so far only been
approved by the FDA as a short-term therapeutic option for improving
appetite in anorexic dogs.